What's new?

2 December 2021 – DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. DMC is commercial with its firs...

• Milan based Epsilen Bio is acquired by Chroma Medicine, which launches today with $125M in financing • Epsilen Bio, now a wholly owned subsidiary of Chroma Medicine, will continue to conduct groundbreaking epigenetic editing R&D in Milan in collaboration with SR-Tiget • Epsilen Bio was founded in 2019 with se...

Horizons Ventures and Sofinnova Partners Co-Lead Investment in Market-leading Life Sciences Software Company That Transforms the Way Scientists Automate Experimentation and Share Insights   November 16, 2021 04:30 AM Eastern Standard Time

November 09, 2021 03:00 AM Eastern Standard Time PARIS--(BUSINESS WIRE)--Home Biosciences, Europe’s first venture builder fully dedicated to biotech, announced today a $15 million Seed financing led by Redmile Group and Sofinnova Partners.  

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Nov 5, 2021-- GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics AG, from which GlycoEra was...

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Par...

The new funds will help accelerate the commercialization of the company’s Enzymatic DNA Printing Platform Sofinnova Partners was the company’s first institutional investor and led its seed round in 2016  

- Advancing First-In-Class CD8 Treg Modulators to Restore Immune Balance SEATTLE, Oct. 26, 2021 /PRNewswire/ -- Mozart Therapeutics, Inc., a new biopharmaceutical company targeting a novel immune pathway to change the course of autoimmune and inflammatory disease, today announced a $55 Million Series A Financing le...

Funding will support continued development of CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase product candidate, for the treatment of hypertension, primary aldosteronism and chronic kidney disease CINCINNATI, Oct. 12, 2021 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) today a...

- Financing round with top-tier life science venture capitalists, led by Athos Service and MIG Capital, joined by existing shareholders - The new funds will be used to advance iOmx' lead programs IMT-07 and IMT-18, both addressing novel immune checkpoint targets in oncology